Targeting ALK With Crizotinib in Pediatric Anaplastic Large Cell Lymphoma and Inflammatory Myofibroblastic Tumor: A Children's Oncology Group Study

Lung, Respiratory and Thoracic CancerLymphoma

Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study

Ann Oncol.

Novello S, Mazières J, Oh IJ, de Castro J, Migliorino MR, Helland Å, Dziadziuszko R, Griesinger F, Kotb A, Zeaiter A, Cardona A, Balas B, Johannsdottir HK, Das-Gupta A, Wolf J

doi: 10.1093/annonc/mdy121.

Lung Cancer

Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations.

1Department of Medical Oncology, University Hospital Basel, Basel, Switzerland.

Sarcoma

Inflammatory myofibroblastic tumor: The experience of the European pediatric Soft Tissue Sarcoma Study Group (EpSSG)

Eur J Cancer.

Casanova M, Brennan B, Alaggio R, Kelsey A, Orbach D, van Noesel MM, Corradini N, Minard-Colin V, Zanetti I, Bisogno G, Gallego S, Merks JHM, De Salvo GL, Ferrari A

doi: 10.1016/j.ejca.2019.12.021.

Lung, Respiratory and Thoracic CancerRadio-OncologyLymphoma

Alectinib versus crizotinib in treatment-naïve anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study

Ann Oncol.

Gadgeel S, Peters S, Mok T, Shaw AT, Kim DW, Ou SI, Pérol M, Wrona A, Novello S, Rosell R, Zeaiter A, Liu T, Nüesch E, Balas B, Camidge DR

doi: 10.1093/annonc/mdy405.

Lymphoma

Rationale for targeting tumor cells in their microenvironment for mantle cell lymphoma treatment

Leuk Lymphoma.

Papin A, Le Gouill S, Chiron D

doi: 10.1080/

Lung, Respiratory and Thoracic Cancer

Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370)

J Thorac Oncol.

Spigel DR, Reynolds C, Waterhouse D, Garon EB, Chandler J, Babu S, Thurmes P, Spira A, Jotte R, Zhu J, Lin WH, Blumenschein G Jr.

doi: 10.1016/j.jtho.2018.02.022.

Central Nervous System TumorsEndocrine and Neuroendocrine Tumors (NET)Genitourinary CancerGynecologic CancerLung, Respiratory and Thoracic CancerSarcomaMyeloproliferative Neoplasms (MPNs)

Brigatinib versus Crizotinib in Anaplastic Lymphoma Kinase (ALK) Inhibitor-Naive Advanced ALK-Positive Non-Small Cell Lung Cancer: Final Results of the Phase 3 ALTA-1L Trial

J Thorac Oncol

Camidge DR, Kim HR, Ahn MJ, Yang JC, Han JY, Hochmair MJ, Lee KH, Delmonte A, Garcia Campelo MR, Kim DW, Griesinger F, Felip E, Califano R, Spira AI, Gettinger SN, Tiseo M, Lin HM, Liu Y, Vranceanu F, Niu H, Zhang P, Popat S

doi: 10.1016/j.jtho.2021.07.035

Lymphoma

Chromosome 20 loss is characteristic of breast implant-associated anaplastic large cell lymphoma

Blood.

Los-de Vries GT, de Boer M, van Dijk E, Stathi P, Hijmering NJ, Roemer MGM, Mendeville M, Miedema DM, de Boer JP, Rakhorst HA, van Leeuwen FE, van der Hulst RRWJ, Ylstra B, de Jong D

doi: 10.1182/blood.2020005372.

Lymphoma

Stem Cell Transplantation and Vinblastine Monotherapy for Relapsed Pediatric Anaplastic Large Cell Lymphoma: Results of the International, Prospective ALCL-Relapse Trial

J Clin Oncol.

Knörr F, Brugières L, Pillon M, Zimmermann M, Ruf S, Attarbaschi A, Mellgren K, Burke GAA, Uyttebroeck A, Wróbel G, Beishuizen A, Aladjidi N, Reiter A, Woessmann W, European Inter-Group for Childhood Non-Hodgkin Lymphoma

doi: 10.1200/JCO.20.00157.

Related content

Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study

Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations.

Inflammatory myofibroblastic tumor: The experience of the European pediatric Soft Tissue Sarcoma Study Group (EpSSG)

Alectinib versus crizotinib in treatment-naïve anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study

Rationale for targeting tumor cells in their microenvironment for mantle cell lymphoma treatment

Phase 1/2 Study of the Safety and Tolerability of Nivolumab Plus Crizotinib for the First-Line Treatment of Anaplastic Lymphoma Kinase Translocation - Positive Advanced Non-Small Cell Lung Cancer (CheckMate 370)

Brigatinib versus Crizotinib in Anaplastic Lymphoma Kinase (ALK) Inhibitor-Naive Advanced ALK-Positive Non-Small Cell Lung Cancer: Final Results of the Phase 3 ALTA-1L Trial

Chromosome 20 loss is characteristic of breast implant-associated anaplastic large cell lymphoma

Stem Cell Transplantation and Vinblastine Monotherapy for Relapsed Pediatric Anaplastic Large Cell Lymphoma: Results of the International, Prospective ALCL-Relapse Trial